In less than 90 minutes, a new, less invasive electrical stimulation technique has been found to improve breathing in people with sleep apnea. The technique, which involves percutaneous hypoglossal ...

If you have obstructive sleep apnea (OSA)—a condition that causes a partial or complete collapse of your upper airway while sleeping—you’re likely familiar with continuous positive airway pressure ...

The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity. Photo courtesy ...

Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition ...

Along with diet and exercise, sleep is the third pillar of health. And frankly, a good night's sleep is often the answer to whatever ails you. But for 30 million people in the United States, sleep ...

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Dear Savvy Senior: I’ve been diagnosed with sleep apnea and have been trying to use a CPAP device for the past six months but can’t tolerate it. Are there any alternative treatment options? — Sleepy ...

It could be a game-changer for the millions of Americans who suffer from sleep apnea. A new first-of-its-kind pill could change the way people treat the condition, which can lead to serious health ...

Sleep apnea is a prevalent sleep disorder that affects millions of individuals worldwide, yet it often goes undiagnosed and untreated. This condition not only disrupts sleep patterns but also poses ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea. The agency ...

LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...